CVRx to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

CVRx, a medical device company specializing in neuromodulation solutions for cardiovascular diseases, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:45 pm ET. The presentation will be available via a live audio webcast on the company’s investor relations page, with a replay accessible for 90 days. CVRx is known for its FDA-approved Barostim device that alleviates symptoms of heart failure through electrical pulses to baroreceptors, receiving both FDA Breakthrough Device designation and CE Mark approval.

MINNEAPOLIS, Dec. 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022. The Company is scheduled to present at 3:45 pm Eastern Time the same day via webcast.

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com. A replay of the webcast will be archived on the website for approximately 90 days.

About CVRx, Inc.

CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:

Mark Klausner or Mike Vallie
ICR Westwicke
ir@cvrx.com

Media Contact:

Lisa Murray
Trevi Communications, Inc.
978.750.0333 / 617.835.0396
lisa@trevicomm.com

FAQ

What is the date and time of CVRx's presentation at the J.P. Morgan Healthcare Conference?

CVRx will present on January 11, 2022, at 3:45 pm Eastern Time.

Where can I watch the CVRx presentation live?

The presentation will be available via live audio webcast on CVRx's investor relations page.

What is the main technology discussed in the CVRx press release?

The press release discusses the Barostim device, which treats heart failure symptoms using neuromodulation.

What FDA designation does CVRx's Barostim device hold?

The Barostim device has received FDA Breakthrough Device designation.

Is Barostim approved for use outside the U.S.?

Yes, Barostim has received CE Mark approval for use in the European Economic Area.